The choice of prodrugs for gene directed enzyme prodrug therapy of cancer

Prodrugs are chemicals that are pharmacodynamically and toxicologically inert but which can be converted to highly active species. In cancer chemotherapy, enzyme activated prodrugs have been effective against certain animal tumours. However, in the clinic it has been found that human tumours contain...

Full description

Saved in:
Bibliographic Details
Published inGene therapy Vol. 2; no. 10; p. 702
Main Author Connors, T A
Format Journal Article
LanguageEnglish
Published England 01.12.1995
Subjects
Online AccessGet more information

Cover

Loading…
Abstract Prodrugs are chemicals that are pharmacodynamically and toxicologically inert but which can be converted to highly active species. In cancer chemotherapy, enzyme activated prodrugs have been effective against certain animal tumours. However, in the clinic it has been found that human tumours containing appropriately high levels of the activating enzymes were rare and not associated with any particular type of tumour. Gene directed enzyme prodrug therapy (GDEPT) attempts to overcome this problem by killing tumour cells by the activation of a prodrug after the gene encoding for an activating enzyme has been targeted to the malignant cell. Here we summarise the various enzyme/prodrug systems that have been proposed for cancer therapy and comment on their suitability for GDEPT. This is because systems developed for other applications such as antibody directed enzyme prodrug therapy (ADEPT) may not be suitable for GDEPT. What is required are nontoxic prodrugs that can be converted intracellularly to highly cytotoxic metabolites that are not cell cycle specific in their mechanism of action. The active drugs released should also be readily diffusible and exert a bystander effect. Alkylating agents best meet these criteria. An example of a suitable enzyme/prodrug system may be a bacterial nitroreductase that can convert a relatively nontoxic monofunctional alkylating agent to a difunctional alkylating agent that is some ten thousand times more cytotoxic.
AbstractList Prodrugs are chemicals that are pharmacodynamically and toxicologically inert but which can be converted to highly active species. In cancer chemotherapy, enzyme activated prodrugs have been effective against certain animal tumours. However, in the clinic it has been found that human tumours containing appropriately high levels of the activating enzymes were rare and not associated with any particular type of tumour. Gene directed enzyme prodrug therapy (GDEPT) attempts to overcome this problem by killing tumour cells by the activation of a prodrug after the gene encoding for an activating enzyme has been targeted to the malignant cell. Here we summarise the various enzyme/prodrug systems that have been proposed for cancer therapy and comment on their suitability for GDEPT. This is because systems developed for other applications such as antibody directed enzyme prodrug therapy (ADEPT) may not be suitable for GDEPT. What is required are nontoxic prodrugs that can be converted intracellularly to highly cytotoxic metabolites that are not cell cycle specific in their mechanism of action. The active drugs released should also be readily diffusible and exert a bystander effect. Alkylating agents best meet these criteria. An example of a suitable enzyme/prodrug system may be a bacterial nitroreductase that can convert a relatively nontoxic monofunctional alkylating agent to a difunctional alkylating agent that is some ten thousand times more cytotoxic.
Author Connors, T A
Author_xml – sequence: 1
  givenname: T A
  surname: Connors
  fullname: Connors, T A
  organization: Centre for Polymer Therapeutics, School of Pharmacy, London, UK
BackLink https://www.ncbi.nlm.nih.gov/pubmed/8750009$$D View this record in MEDLINE/PubMed
BookMark eNo1j8tqwzAURLVISZO0n1DQDxj0sh7LEvoIBLJJ10G-uopdasnIzsL9-qY0XQ0Dc4aZNVmknHBBVsxpVxku7D1Zj-MnY0wZK5ZkaU19NW5FdscWKbS5A6Q50qHkUC7nkcZc6BkT0tAVhAkDxfQ99_ifoFOLxQ_zLwQ-AZYHchf914iPN92Qj9eX4_a92h_edtvnfTUIaaYqeoW2QeW4CaaRQfsaFLeaqeBkozx3UuhohJOcSwm1dgDhutYz0NHWVmzI01_vcGl6DKehdL0v8-l2SfwAaXlIRA
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
ExternalDocumentID 8750009
Genre Research Support, Non-U.S. Gov't
Journal Article
Review
GroupedDBID ---
-Q-
.55
.GJ
0R~
29H
2WC
36B
39C
3V.
4.4
406
53G
5GY
70F
7X7
88E
8AO
8C1
8FE
8FH
8FI
8FJ
8G5
8R4
8R5
AACDK
AANZL
AASML
AATNV
AAYZH
AAZLF
ABAKF
ABAWZ
ABDBF
ABJNI
ABLJU
ABUWG
ABZZP
ACAOD
ACGFS
ACKTT
ACMJI
ACPRK
ACRQY
ACZOJ
ADBBV
ADFRT
ADHDB
AEFQL
AEJRE
AEMSY
AENEX
AEVLU
AEXYK
AFBBN
AFKRA
AFSHS
AGAYW
AGEZK
AGHAI
AGQEE
AHMBA
AHSBF
AIGIU
AILAN
AJRNO
ALFFA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMYLF
ASPBG
AVWKF
AXYYD
AZFZN
AZQEC
B0M
BAWUL
BBNVY
BENPR
BHPHI
BKKNO
BPHCQ
BVXVI
CAG
CCPQU
CGR
COF
CS3
CUY
CVF
DIK
DNIVK
DPUIP
DU5
DWQXO
E3Z
EAD
EAP
EBC
EBLON
EBS
ECM
EE.
EIF
EIOEI
EJD
EMB
EMK
EMOBN
EPL
ESX
F5P
FDQFY
FEDTE
FERAY
FIGPU
FIZPM
FSGXE
FYUFA
GNUQQ
GUQSH
HCIFZ
HMCUK
HVGLF
HZ~
IAO
IEA
IGG
IHR
IHW
INH
INR
ISR
ITC
IWAJR
JSO
JZLTJ
KQ8
LK8
M1P
M2O
M7P
N9A
NAO
NPM
NQJWS
O9-
OK1
OVD
PQQKQ
PROAC
PSQYO
Q2X
RNS
RNT
RNTTT
SNX
SNYQT
SOHCF
SRMVM
SV3
SWTZT
TAOOD
TBHMF
TDRGL
TEORI
TR2
TSG
TUS
UDS
UKHRP
W2D
X7M
Y6R
~8M
ID FETCH-LOGICAL-p237t-fa4e8be4917d7b3d6a5c418604d93b4a19326f72931133c569ccd750a0c6f8582
ISSN 0969-7128
IngestDate Tue Oct 15 23:16:02 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 10
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-p237t-fa4e8be4917d7b3d6a5c418604d93b4a19326f72931133c569ccd750a0c6f8582
PMID 8750009
ParticipantIDs pubmed_primary_8750009
PublicationCentury 1900
PublicationDate 1995-12-01
PublicationDateYYYYMMDD 1995-12-01
PublicationDate_xml – month: 12
  year: 1995
  text: 1995-12-01
  day: 01
PublicationDecade 1990
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Gene therapy
PublicationTitleAlternate Gene Ther
PublicationYear 1995
SSID ssj0004782
Score 1.8986379
SecondaryResourceType review_article
Snippet Prodrugs are chemicals that are pharmacodynamically and toxicologically inert but which can be converted to highly active species. In cancer chemotherapy,...
SourceID pubmed
SourceType Index Database
StartPage 702
SubjectTerms Antineoplastic Agents - administration & dosage
Antineoplastic Agents - metabolism
Antineoplastic Agents - therapeutic use
Biotransformation
Enzymes - administration & dosage
Enzymes - biosynthesis
Enzymes - therapeutic use
Genetic Therapy - methods
Humans
Neoplasms - drug therapy
Prodrugs - administration & dosage
Prodrugs - metabolism
Prodrugs - therapeutic use
Title The choice of prodrugs for gene directed enzyme prodrug therapy of cancer
URI https://www.ncbi.nlm.nih.gov/pubmed/8750009
Volume 2
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ07a8MwEMdF09KSpfQV-kZDt-BiW5IfYyktaSGZEsgWJFnqFCcEd2g-fU8POya09LGYYMnGuZ99Psn63yF0lwumVZjkgY6NJEfFOhBaiiBLKGdcmJw3Rjs8HCWDCX2dsukmm4VVl1TiXq6_1JX8hyrsA65GJfsHss1JYQf8Br6wBcKw_TVjcF_wrNuFy-ALV-9vNsGCqYys-u59BSGlKtcfc1X36DvRlf22Lg31VTtENYmo6x7NFwpTlNoVUxv72c_CS-dYa9WFn_IDJmnkxdje-8VtyGHLlaVWCV21zLicWzvCCMdEZj82buWx9i0d1Ekz45BGZlqlFrCmtqpXc4FdtO-7b0X79q0_PkKHPlzHD872x2hHlSfoYOgXJJyiF0CAHQK80LhGgAEBNghwjQA7BHUP7A1sDnIIztDk-Wn8OAh8dYpgGZO0CjSnKhOKwni3SAUpEs4kjbIkpEVOBOU2MtYwdiFRRIhkSS5lAX-KhzLRGcviHtotF6U6Rzjm8CjxIo5UyqiCkJ2AW5Ra5ZnQIafRBeo5I8yWLgXJzFvn8ruGK9Td3AHXaE_DHa9uIHyqxK01_SdwNh4a
link.rule.ids 783
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+choice+of+prodrugs+for+gene+directed+enzyme+prodrug+therapy+of+cancer&rft.jtitle=Gene+therapy&rft.au=Connors%2C+T+A&rft.date=1995-12-01&rft.issn=0969-7128&rft.volume=2&rft.issue=10&rft.spage=702&rft_id=info%3Apmid%2F8750009&rft_id=info%3Apmid%2F8750009&rft.externalDocID=8750009
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0969-7128&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0969-7128&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0969-7128&client=summon